ES2282546T3 - Derivados de adamantano para el tratamiento de enfermedades inflamatorias, inmunitarias y cardiovasculares. - Google Patents

Derivados de adamantano para el tratamiento de enfermedades inflamatorias, inmunitarias y cardiovasculares. Download PDF

Info

Publication number
ES2282546T3
ES2282546T3 ES03013989T ES03013989T ES2282546T3 ES 2282546 T3 ES2282546 T3 ES 2282546T3 ES 03013989 T ES03013989 T ES 03013989T ES 03013989 T ES03013989 T ES 03013989T ES 2282546 T3 ES2282546 T3 ES 2282546T3
Authority
ES
Spain
Prior art keywords
formula
compound
solvate
pharmaceutically acceptable
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03013989T
Other languages
English (en)
Spanish (es)
Inventor
Mark Astrazeneca R&D Charnwood Furber
Michael Vertex Pharmaceuticals Ltd. Mortimore
Lilian Astrazeneca R&D Charnwood Alcaraz
Timothy Astrazeneca R&D Charnwood Luker
Philip Astrazeneca R&D Charnwood Thorne
Paul Astrazeneca R&D Charnwood Willis
Austen AstraZeneca R&D Charnwood Pimm
Moya AstraZeneca R&D Charnwood Caffrey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9904651A external-priority patent/SE9904651D0/xx
Priority claimed from GB0015744A external-priority patent/GB0015744D0/en
Priority claimed from GB0017942A external-priority patent/GB0017942D0/en
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES2282546T3 publication Critical patent/ES2282546T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
ES03013989T 1999-12-17 2000-12-12 Derivados de adamantano para el tratamiento de enfermedades inflamatorias, inmunitarias y cardiovasculares. Expired - Lifetime ES2282546T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
SE9904651A SE9904651D0 (sv) 1999-12-17 1999-12-17 Novel compounds
SE9904651 1999-12-17
GB0015744A GB0015744D0 (en) 2000-06-27 2000-06-27 Novel compounds
GB0015744 2000-06-27
GB0017942 2000-07-22
GB0017942A GB0017942D0 (en) 2000-07-22 2000-07-22 Novel compounds

Publications (1)

Publication Number Publication Date
ES2282546T3 true ES2282546T3 (es) 2007-10-16

Family

ID=27255782

Family Applications (4)

Application Number Title Priority Date Filing Date
ES00986155T Expired - Lifetime ES2215777T3 (es) 1999-12-17 2000-12-12 Derivados de adamantano.
ES03013990T Expired - Lifetime ES2294219T3 (es) 1999-12-17 2000-12-12 Derivados de adamantano para el tratamiento de enfermedades inflamatorias, inmunitarias y cardiovasculares.
ES03013989T Expired - Lifetime ES2282546T3 (es) 1999-12-17 2000-12-12 Derivados de adamantano para el tratamiento de enfermedades inflamatorias, inmunitarias y cardiovasculares.
ES03013991T Expired - Lifetime ES2279031T3 (es) 1999-12-17 2000-12-12 Derivados de adamantano para el tratamiento de enfermedades inflamatorias, inmunitarias y cardiovasculares.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES00986155T Expired - Lifetime ES2215777T3 (es) 1999-12-17 2000-12-12 Derivados de adamantano.
ES03013990T Expired - Lifetime ES2294219T3 (es) 1999-12-17 2000-12-12 Derivados de adamantano para el tratamiento de enfermedades inflamatorias, inmunitarias y cardiovasculares.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES03013991T Expired - Lifetime ES2279031T3 (es) 1999-12-17 2000-12-12 Derivados de adamantano para el tratamiento de enfermedades inflamatorias, inmunitarias y cardiovasculares.

Country Status (32)

Country Link
US (5) US6881754B2 (enExample)
EP (5) EP1862451A1 (enExample)
JP (2) JP3710418B2 (enExample)
KR (2) KR20070012883A (enExample)
CN (1) CN1312120C (enExample)
AR (1) AR035325A1 (enExample)
AT (4) ATE358117T1 (enExample)
AU (2) AU780506B2 (enExample)
BR (1) BRPI0016395B8 (enExample)
CA (1) CA2393352C (enExample)
CO (1) CO5251381A1 (enExample)
CY (3) CY1106357T1 (enExample)
CZ (1) CZ20022093A3 (enExample)
DE (4) DE60034155T2 (enExample)
DK (4) DK1352897T3 (enExample)
EE (1) EE05134B1 (enExample)
ES (4) ES2215777T3 (enExample)
HK (1) HK1046678B (enExample)
HU (1) HUP0300616A3 (enExample)
IL (2) IL150124A0 (enExample)
IS (1) IS2246B (enExample)
MX (1) MXPA02005789A (enExample)
MY (1) MY125978A (enExample)
NO (1) NO328682B1 (enExample)
NZ (1) NZ519378A (enExample)
PL (1) PL200836B1 (enExample)
PT (4) PT1352896E (enExample)
SI (1) SI1352895T1 (enExample)
SK (1) SK286987B6 (enExample)
TR (1) TR200401432T4 (enExample)
TW (1) TWI258462B (enExample)
WO (1) WO2001044170A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904505D0 (sv) 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) * 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SE9904738D0 (sv) 1999-12-22 1999-12-22 Astra Pharma Prod Novel compounds
PA8557501A1 (es) 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
PA8591801A1 (es) 2002-12-31 2004-07-26 Pfizer Prod Inc Inhibidores benzamidicos del receptor p2x7.
US7071223B1 (en) 2002-12-31 2006-07-04 Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor
SE0300445D0 (sv) * 2003-02-18 2003-02-18 Astrazeneca Ab New combination
SE0300480D0 (sv) * 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
ATE355273T1 (de) * 2003-05-12 2006-03-15 Pfizer Prod Inc Benzamidinhibitoren des p2x7-rezeptors
WO2004105796A1 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate
KR20060037258A (ko) * 2003-05-29 2006-05-03 아스트라제네카 아베 Ｐ2Ｘ7-수용체 길항제 및 종양 괴사 인자 α를 포함하는제약 조성물
WO2004105797A1 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination
JP2008504363A (ja) * 2004-06-29 2008-02-14 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Ｐ２ｘ７受容体のベンズアミド阻害剤を利用する併用療法
RU2006146675A (ru) * 2004-06-29 2008-07-10 Пфайзер Продактс Инк. (Us) Способ получения производных 5-[4-(2-гидроксипропил)-3,5-диоксо-4,5-дигидро-3н-[1,2,4] триазин-2-ил] бензамида снятием защиты с промежуточных продуктов, содержащих защищенный гидроксил
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
US20060063834A1 (en) * 2004-09-09 2006-03-23 Frangioni John V Substituted adamantanes, and methods of making the same
SE0402925D0 (sv) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
US20080207577A1 (en) * 2005-07-11 2008-08-28 Astrazeneca Ab Combination I
WO2007008157A1 (en) * 2005-07-11 2007-01-18 Astrazeneca Ab New combination 2
TW200819416A (en) * 2006-09-05 2008-05-01 Astrazeneca Ab Novel process 470
CA2713322C (en) 2008-02-06 2017-01-17 Astrazeneca Ab Diazaspiro [5.5] undecane derivatives and their use in the treatment of pulmonary disorders
NZ587799A (en) 2008-03-25 2012-06-29 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
BRPI1014902A2 (pt) 2009-04-14 2016-04-19 Affectis Pharmaceuticals Ag composto antagonista de p2x7r, sua composição e seus usos
GB2469915A (en) * 2009-04-30 2010-11-03 Astrazeneca Ab 2-chloro-5-[3-[(3-hydroxypropyl)amino]propyl]-N-(tricyclo[3.3.1.13,7]dec- 1-ylmethyl)-benzamide hydrochloride salt
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
EP2322149A1 (en) 2009-11-03 2011-05-18 Universidad del Pais Vasco Methods and compositions for the treatment of ischemia
MX2012013075A (es) 2010-05-14 2012-12-17 Affectis Pharmaceuticals Ag Metodos novedosos para preparacion de antagonistas p2x7r.
JP2013249256A (ja) * 2010-09-15 2013-12-12 Astellas Pharma Inc 脂肪性肝疾患治療薬
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
RU2014106611A (ru) 2011-07-22 2015-08-27 Актелион Фармасьютиклз Лтд Производные гетероциклических амидов в качестве антагонистов р2х7 рецептора
NZ628910A (en) 2012-01-20 2016-02-26 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
PL2931717T3 (pl) 2012-12-12 2017-05-31 Actelion Pharmaceuticals Ltd. Pochodne indolokarboksyamidu jako antagoniści receptora p2x7
AR094053A1 (es) 2012-12-18 2015-07-08 Actelion Pharmaceuticals Ltd Derivados de indol carboxamida como antagonistas del receptor p2x₇
EP2956457B1 (en) 2013-01-22 2016-11-23 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
ES2616114T3 (es) 2013-01-22 2017-06-09 Actelion Pharmaceuticals Ltd. Derivados de amida heterocíclica como antagonistas del receptor P2X7
EP4479366A2 (en) * 2022-02-15 2024-12-25 The Children's Medical Center Corporation Compositions and methods relating to atp/p2x7r signaling inhibition
EP4230196A1 (en) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Compounds for use in the treatment of dystrophinopathies
WO2025024881A1 (en) * 2023-07-28 2025-02-06 The University Of Sydney Adamantyl p2x7 receptor antagonists and their use in the treatment of cardiovascular diseases

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3029241A (en) * 1962-04-10 Phenylpbperazinylacyl anilines
US3464998A (en) * 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
US3732305A (en) * 1970-03-03 1973-05-08 Us Army S-substituted thiosulfuric acid derivatives and preparation thereof
US3789072A (en) * 1970-04-22 1974-01-29 Squibb & Sons Inc Carboxamides
FR2346011A1 (fr) 1976-02-02 1977-10-28 Orsymonde Acetanilido-piperazines
ZA825719B (en) 1981-09-03 1983-06-29 Recordati Chem Pharm Alkanoylanilides
CA2015473C (en) 1989-04-28 1998-04-14 Iwao Kinoshita Triphenylmethane derivatives
US6021024A (en) * 1992-02-21 2000-02-01 Kabushiki Kaisha Toshiba Magnetic disk drive having a constant skew angle
CA2091194A1 (en) 1992-04-08 1993-10-09 Richard D. Connell 2-oxo-ethyl derivatives as immunosuppressants
DE69322707T2 (de) 1992-07-31 1999-08-19 Bristol-Myers Squibb Company Diphenyl Oxazole-, Thiazole- und Imidazole-Derivate als Inhibitoren der Wiederaufnahme des Adenosins
AU682051B2 (en) 1993-08-10 1997-09-18 James Black Foundation Limited Gastrin and CCK receptor ligands
US5530018A (en) * 1994-02-04 1996-06-25 G. D. Searle & Co. Meso-azanoradamantanes
GB9409150D0 (en) 1994-05-09 1994-06-29 Black James Foundation Cck and gastrin receptor ligands
DE69530081T2 (de) 1994-05-27 2003-12-24 James Black Foundation Ltd., London Gastrin- und cck-antagonisten
CA2200468A1 (en) 1994-10-27 1996-05-09 Wayne J. Thompson Muscarine antagonists
DE19608653A1 (de) 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704544D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704546D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
AU1903799A (en) * 1997-12-05 1999-06-28 Eisai Co. Ltd. Compositions and methods for modulating the activity of fibroblast growth factor
US6018089A (en) * 1997-12-09 2000-01-25 Shell Oil Company Process for separating linear internal olefins from branched internal olefins
AU1924099A (en) 1997-12-18 1999-07-05 Lyonnaise Industrielle Pharmaceutique (Lipha) Piperazine derivatives useful as hypoglycemic agents
WO1999059582A1 (en) 1998-05-19 1999-11-25 Centaur Pharmaceuticals, Inc. Amide therapeutics for the treatment of inflammatory bowel disease
WO2000061569A1 (en) 1999-04-09 2000-10-19 Astrazeneca Ab Adamantane derivatives
SE9901875D0 (sv) 1999-05-25 1999-05-25 Astra Pharma Prod Novel compounds
SE9904505D0 (sv) 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) * 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SE9904652D0 (sv) * 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
SE9904738D0 (sv) * 1999-12-22 1999-12-22 Astra Pharma Prod Novel compounds
GB0013737D0 (en) 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
US6555451B1 (en) * 2001-09-28 2003-04-29 The United States Of America As Represented By The Secretary Of The Navy Method for making shallow diffusion junctions in semiconductors using elemental doping
SE0103836D0 (sv) 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
SE0200920D0 (sv) 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300480D0 (sv) * 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
SE0302488D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab New combination
SA05260265A (ar) 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
SE0402925D0 (sv) 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds

Also Published As

Publication number Publication date
NZ519378A (en) 2004-02-27
US6881754B2 (en) 2005-04-19
US20050049303A1 (en) 2005-03-03
US20030013704A1 (en) 2003-01-16
EE05134B1 (et) 2009-02-16
NO328682B1 (no) 2010-04-26
ATE261933T1 (de) 2004-04-15
NO20022856D0 (no) 2002-06-14
DE60009147D1 (de) 2004-04-22
AU780506B2 (en) 2005-03-24
ATE350364T1 (de) 2007-01-15
DE60009147T2 (de) 2005-04-21
JP3710418B2 (ja) 2005-10-26
US7297818B2 (en) 2007-11-20
ATE376994T1 (de) 2007-11-15
PL200836B1 (pl) 2009-02-27
DK1352895T3 (da) 2007-06-11
TR200401432T4 (tr) 2004-08-23
CY1106357T1 (el) 2011-10-12
DE60034155T2 (de) 2007-12-13
EP1352897A3 (en) 2003-12-03
IS2246B (is) 2007-06-15
EP1242364B1 (en) 2004-03-17
ES2215777T3 (es) 2004-10-16
EP1352896B1 (en) 2007-10-31
PL355913A1 (en) 2004-05-31
CN1312120C (zh) 2007-04-25
EP1242364A1 (en) 2002-09-25
NO20022856L (no) 2002-08-16
CY1107838T1 (el) 2013-06-19
WO2001044170A1 (en) 2001-06-21
MY125978A (en) 2006-09-29
IS6406A (is) 2002-05-31
EP1352895A3 (en) 2003-12-03
BR0016395A (pt) 2002-08-27
EP1352896A3 (en) 2003-12-03
PT1242364E (pt) 2004-07-30
PT1352895E (pt) 2007-05-31
JP2003517035A (ja) 2003-05-20
PT1352897E (pt) 2007-03-30
EP1352897B1 (en) 2007-01-03
DE60032823T2 (de) 2007-11-08
IL189758A0 (en) 2008-06-05
IL150124A0 (en) 2002-12-01
AU2244401A (en) 2001-06-25
SK286987B6 (sk) 2009-08-06
US20070082957A1 (en) 2007-04-12
DK1242364T3 (da) 2004-06-21
DK1352897T3 (da) 2007-04-10
CA2393352C (en) 2011-08-30
CN1434794A (zh) 2003-08-06
US7132457B2 (en) 2006-11-07
CZ20022093A3 (cs) 2003-01-15
MXPA02005789A (es) 2002-09-18
KR20070012883A (ko) 2007-01-29
ATE358117T1 (de) 2007-04-15
US20090176853A1 (en) 2009-07-09
AR035325A1 (es) 2004-05-12
HK1046678A1 (en) 2003-01-24
EP1352895A2 (en) 2003-10-15
HK1046678B (en) 2004-12-03
CA2393352A1 (en) 2001-06-21
HUP0300616A2 (hu) 2003-07-28
BR0016395B1 (pt) 2013-10-08
AU2005202321A1 (en) 2005-06-23
DE60034155D1 (de) 2007-05-10
KR100710110B1 (ko) 2007-04-20
EE200200330A (et) 2003-10-15
HK1057035A1 (en) 2004-03-12
BRPI0016395B8 (pt) 2021-05-25
EP1352896A2 (en) 2003-10-15
AU2005202321B2 (en) 2008-05-22
DK1352896T3 (da) 2008-01-28
EP1352897A2 (en) 2003-10-15
CO5251381A1 (es) 2003-02-28
SI1352895T1 (sl) 2007-08-31
SK8412002A3 (en) 2003-02-04
TWI258462B (en) 2006-07-21
DE60032823D1 (de) 2007-02-15
DE60036968T2 (de) 2008-08-14
KR20020061646A (ko) 2002-07-24
DE60036968D1 (de) 2007-12-13
ES2294219T3 (es) 2008-04-01
CY1106602T1 (el) 2012-01-25
JP2005320340A (ja) 2005-11-17
US20080139636A1 (en) 2008-06-12
HUP0300616A3 (en) 2004-08-30
ES2279031T3 (es) 2007-08-16
PT1352896E (pt) 2007-12-19
EP1862451A1 (en) 2007-12-05
EP1352895B1 (en) 2007-03-28

Similar Documents

Publication Publication Date Title
ES2282546T3 (es) Derivados de adamantano para el tratamiento de enfermedades inflamatorias, inmunitarias y cardiovasculares.
US10806712B2 (en) Small molecule inhibitors of STAT3 with anti-tumor activity
ES2274110T3 (es) Derivados de n-adamantilmetilo e intermedios como composiciones farmaceuticas y procedimientos para su preparacion.
KR100249068B1 (ko) 아미디노 화합물 이의 제조방법 및 이를 포함하는 약제학적 조성물
DE602004005016T2 (de) Biphenylcarboxamidderivate und ihre verwendung als p38 kinase inhibitoren
JP2004506611A (ja) アダマンタン誘導体
EP4037676A1 (en) Cannabinoid derivatives
DE69408580T2 (de) 2-amino-1,2,3,4-tetrahydronaphthalenderivate mit cardiovaskulärer wirkung
Hirose et al. Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 3. Evaluation of 5-amino-linked thiazolo [5, 4-d] pyrimidine and thiazolo [5, 4-b] pyridine derivatives
JP3299990B2 (ja) 神経変性状態およびｃｎｓ外傷関連状態の処置のための３−ヘテロアリール−４（３ｈ）−キナゾリノン類のアトロプ異性体
JP2023534674A (ja) スルホニル尿素誘導体及びその医薬用途
CN110483487B (zh) 一种2-硫甲基吡唑嘧啶酮类化合物、其制备方法、药物组合物及应用
PL172056B1 (pl) Sposób wytwarzania pochodnych 2-amino-1,2,3,4-tetrahydronaftalenu PL
DE69405815T2 (de) Acylharnstoffe
DE69907845T2 (de) Sulfonamid-Derivate
JP2010512339A (ja) Ａｍｐａ受容体増強剤
NL1028600C2 (nl) Verbindingen voor de behandeling van ziekten.
HK1057036A1 (en) Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases
HK1057036B (en) Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases
HK1057035B (en) Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases